Abstract
Germline mutations in the VHL tumour suppressor gene may cause a variety of phenotypes including von Hippel-Lindau (VHL) disease, familial phaeochromocytoma and inherited polycythaemia. VHL disease is a multisystem familial cancer syndrome and is the commonest cause of familial renal cell carcinoma (RCC). VHL disease provides a paradigm for illustrating how studies of a rare familial cancer syndrome can produce advances in clinical medicin and important insights into basic biological processes. Thus the identification of the VHL gene has improved the diagnosis and clinical management of VHL disease and provided insights into the pathogenesis of sporadic clear cell RCC. Functional investigations of the VHL gene product have provided novel information on how cells sense oxygen and the role of hypoxia-response pathways in human tumourigenesis. Such information offers prospects of novel therapeutic interventions for VHL disease and common cancers including RCC.
Keywords: von hippel-lindau (vhl) disease, renal cell carcinoma (rcc), mutations, vhl proteins
Current Molecular Medicine
Title: Von Hippel-Lindau Disease
Volume: 4 Issue: 8
Author(s): Eamonn R. Maher
Affiliation:
Keywords: von hippel-lindau (vhl) disease, renal cell carcinoma (rcc), mutations, vhl proteins
Abstract: Germline mutations in the VHL tumour suppressor gene may cause a variety of phenotypes including von Hippel-Lindau (VHL) disease, familial phaeochromocytoma and inherited polycythaemia. VHL disease is a multisystem familial cancer syndrome and is the commonest cause of familial renal cell carcinoma (RCC). VHL disease provides a paradigm for illustrating how studies of a rare familial cancer syndrome can produce advances in clinical medicin and important insights into basic biological processes. Thus the identification of the VHL gene has improved the diagnosis and clinical management of VHL disease and provided insights into the pathogenesis of sporadic clear cell RCC. Functional investigations of the VHL gene product have provided novel information on how cells sense oxygen and the role of hypoxia-response pathways in human tumourigenesis. Such information offers prospects of novel therapeutic interventions for VHL disease and common cancers including RCC.
Export Options
About this article
Cite this article as:
Maher R. Eamonn, Von Hippel-Lindau Disease, Current Molecular Medicine 2004; 4 (8) . https://dx.doi.org/10.2174/1566524043359827
DOI https://dx.doi.org/10.2174/1566524043359827 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Therapies Against Aggressive and Recurrent Epithelial Cancers by Molecular Targeting Tumor- and Metastasis-Initiating Cells and Their Progenies
Anti-Cancer Agents in Medicinal Chemistry β-Crosslaps as a Marker for Bone Metastases in Renal Cell Cancer
Recent Patents on Biomarkers Systemic and Biophase Bioavailability and Pharmacokinetics of Nanoparticulate Drug Delivery Systems
Current Drug Delivery New Insights into HLA-G and Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) QSAR and the Prediction of T-Cell Epitopes
Current Proteomics Angiogenic and Vascular Modulation by Extracellular Matrix Cleavage Products
Current Pharmaceutical Design The VHL Tumor Suppressor: Master Regulator of HIF
Current Pharmaceutical Design Pharmaceutical Perspectives of HECT-TYPE Ubiquitin Ligase Smurf1
Current Pharmaceutical Design Survivin: Role in Normal Cells and in Pathological Conditions
Current Cancer Drug Targets Matricellular Proteins in Myocardial Infarction
Current Cardiology Reviews Role of C1QBP/p32 and its Therapeutic Potential in Breast Carcinoma and other Cancers
Current Medicinal Chemistry Novel Marine-Derived Anti-Cancer Agents
Current Pharmaceutical Design The Treatment of Autoimmune Hepatitis
Current Clinical Pharmacology Drug-Induced Peripheral Neuropathy: Diagnosis and Management
Current Cancer Drug Targets Development of Nucleic Acid Drugs for Neurological Disorders
Current Topics in Medicinal Chemistry Advanced Glycation End Products: Association with the Pathogenesis of Diseases and the Current Therapeutic Advances
Current Clinical Pharmacology Disorders of Mechanisms of Calcium Metabolism Control as Potential Risk Factors of Prostate Cancer
Current Medicinal Chemistry COX-2, Cell Proliferation and PMA in Head-and-Neck Cancer Cells
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Paraneoplastic Neurological Syndromes - Diagnosis and Management
Current Pharmaceutical Design Emerging Strategies and Challenges for Controlled Delivery of Taxanes: A Comprehensive Review
Current Drug Metabolism